Miromatrix Medical Inc.: management transactions · United States · SEC (Form 4)

About Miromatrix Medical Inc.

Miromatrix Medical Inc. is a U.S.-based biotechnology company that was previously listed on the NASDAQ Capital Market in the United States (United States) under the ticker MIRO and operated in a highly specialized corner of regenerative medicine and organ engineering. The company was founded in 2009 out of research originating at the University of Minnesota, and its core scientific platform is built around proprietary perfusion decellularization and recellularization technology. In practical terms, Miromatrix’s approach involves removing cells from a donor animal organ to preserve the underlying extracellular matrix and vascular architecture, then repopulating that scaffold with human cells in an effort to create a transplantable bioengineered organ. Miromatrix’s development pipeline has focused on three headline programs: mirokidney®, a fully implantable engineered kidney; miroliver®, a fully implantable engineered liver; and miroliverELAP®, an external bioengineered liver-assist system for patients with acute liver failure. The company has also described longer-term ambitions to extend its platform to other organs, including lungs, pancreas, and heart tissue. In investor terms, this is a classic high-risk, high-science platform story: the commercial opportunity is large, but the path to product approval, clinical adoption, and scalable manufacturing is complex and highly regulated. Miromatrix has also highlighted that its work is supported by a sizable patent portfolio and by prior clinical and preclinical data generated from decellularized matrix products. From a competitive standpoint, Miromatrix has occupied a niche position rather than competing in a broad therapeutic market. Its differentiation comes from the combination of organ architecture preservation, human-cell reseeding, and the long-term goal of providing a new source of transplantable organs. That said, the company’s public-market profile changed materially after the 2023 acquisition by United Therapeutics. In December 2023, Miromatrix became a wholly owned subsidiary of United Therapeutics, and the former MIRO shares ceased trading following the transaction. For investors, that is a critical point: Miromatrix should now be understood primarily as an acquired technology platform rather than a standalone listed equity. Geographically, the company is headquartered in Eden Prairie, Minnesota, giving it strong ties to the U.S. biomedical research ecosystem. Its historical footprint has been concentrated in the United States, where its technologies, intellectual property, and clinical development efforts are centered. Recent corporate headlines have been dominated by the acquisition itself and the related contingent value right structure tied to the first implantation of mirokidney in a human patient under specified clinical conditions. Overall, Miromatrix remains an important case study in advanced biotech, combining a long-dated medical mission with meaningful strategic value inside a larger U.S. life sciences platform.